DAMPSKIBSSELSKABET NORDEN A/S – WEEKLY REPORT ON SHARE BUY-BACK
ANNOUNCEMENT NO. 14 - 18 JANUARY 2021
On 4 November 2020, NORDEN initiated a share buy-back programme in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052, (Safe Harbour regulation). The share buy-back programme runs from 4 November 2020 up to and including no later than end February 2021. For details please see announcement no. 87 of 4 November 2020.
Under the share buy-back programme, NORDEN will purchase shares for up to a total of USD 20 million (approximately DKK 126 million). Under the programme, the following transactions have been made:
|Date||Number of shares||Average purchase price (DKK)||Transaction value (DKK)
|Total, last announcement||
Since the share buy-back programme was initiated on 4 November 2020, the total number of repurchased shares is 654,000 at a total amount of DKK 72,858,618.
With the transactions stated above, NORDEN holds a total of 3,013,467 treasury shares, corresponding to 7.40%. The total number of shares in NORDEN is 40,700,000 million. Adjusted for treasury shares, the number of shares is 37,686,533.
Dampskibsselskabet NORDEN A/S
For further information:
Klaus Nyborg, Chairman, tel.: +45 3315 0451
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Norsk Hydro5.3.2021 07:32:40 CET | Press release
Norsk Hydro: Invitation to Investor presentation - Hydro agrees to sell Rolling business area to KPS Capital Partners
Aktieselskabet Schouw & Co.5.3.2021 07:32:10 CET | Press release
Annual Report 2020: The conglomerate shows its strength
Aktieselskabet Schouw & Co.5.3.2021 07:32:00 CET | Pressemeddelelse
Årsrapport 2020: Konglomeratet viser sin styrke
Norsk Hydro5.3.2021 07:31:49 CET | Press release
Norsk Hydro: Hydro agrees to sell Rolling business area to KPS Capital Partners for EUR 1,380 million
Heijmans NV5.3.2021 07:31:39 CET | Press release
Heijmans and AM join forces in Feyenoord City Rotterdam
Hyloris Pharmaceuticals5.3.2021 07:02:18 CET | Press release
Hyloris’ Partner AFT Pharmaceuticals Signs Licensing Agreement with Aguettant for Maxigesic® IV in Eight European Markets
F. Hoffmann-La Roche Ltd5.3.2021 07:02:08 CET | Press release
Roche’s Actemra/RoActemra becomes the first biologic therapy approved by the FDA for slowing the rate of decline in pulmonary function in adults with systemic sclerosis-associated interstitial lung disease, a rare, debilitating condition
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom